J B Chemicals & Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 14, 2025, 2:38 am

Competitors of J B Chemicals & Pharmaceuticals Ltd

All Competitor Stocks of J B Chemicals & Pharmaceuticals Ltd

Quarterly Result

Last Updated: May 31, 2025, 8:47 am

Below is a detailed analysis of the quarterly data for J B Chemicals & Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 949.00 Cr.. The value appears to be declining and may need further review. It has decreased from 963.00 Cr. (Dec 2024) to 949.00 Cr., marking a decrease of 14.00 Cr..
• For Expenses, as of Mar 2025, the value is 723.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 709.00 Cr. (Dec 2024) to 723.00 Cr., marking an increase of 14.00 Cr..
• For Operating Profit, as of Mar 2025, the value is 226.00 Cr.. The value appears to be declining and may need further review. It has decreased from 255.00 Cr. (Dec 2024) to 226.00 Cr., marking a decrease of 29.00 Cr..
• For OPM %, as of Mar 2025, the value is 24.00%. The value appears to be declining and may need further review. It has decreased from 26.00% (Dec 2024) to 24.00%, marking a decrease of 2.00%.
• For Other Income, as of Mar 2025, the value is 14.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Dec 2024) to 14.00 Cr., marking an increase of 6.00 Cr..
• For Interest, as of Mar 2025, the value is 1.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3.00 Cr. (Dec 2024) to 1.00 Cr., marking a decrease of 2.00 Cr..
• For Depreciation, as of Mar 2025, the value is 46.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 42.00 Cr. (Dec 2024) to 46.00 Cr., marking an increase of 4.00 Cr..
• For Profit before tax, as of Mar 2025, the value is 193.00 Cr.. The value appears to be declining and may need further review. It has decreased from 218.00 Cr. (Dec 2024) to 193.00 Cr., marking a decrease of 25.00 Cr..
• For Tax %, as of Mar 2025, the value is 25.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 25.00%.
• For Net Profit, as of Mar 2025, the value is 146.00 Cr.. The value appears to be declining and may need further review. It has decreased from 162.00 Cr. (Dec 2024) to 146.00 Cr., marking a decrease of 16.00 Cr..
• For EPS in Rs, as of Mar 2025, the value is 9.36. The value appears to be declining and may need further review. It has decreased from 10.45 (Dec 2024) to 9.36, marking a decrease of 1.09.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: May 15, 2025, 6:15 am

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: June 12, 2025, 3:16 pm

Below is a detailed analysis of the balance sheet data for J B Chemicals & Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 16.00 Cr..
• For Reserves, as of Mar 2025, the value is 3,418.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,908.00 Cr. (Mar 2024) to 3,418.00 Cr., marking an increase of 510.00 Cr..
• For Borrowings, as of Mar 2025, the value is 22.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 378.00 Cr. (Mar 2024) to 22.00 Cr., marking a decrease of 356.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 819.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 687.00 Cr. (Mar 2024) to 819.00 Cr., marking an increase of 132.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 4,274.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,988.00 Cr. (Mar 2024) to 4,274.00 Cr., marking an increase of 286.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1,985.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,004.00 Cr. (Mar 2024) to 1,985.00 Cr., marking a decrease of 19.00 Cr..
• For CWIP, as of Mar 2025, the value is 47.00 Cr.. The value appears to be declining and may need further review. It has decreased from 76.00 Cr. (Mar 2024) to 47.00 Cr., marking a decrease of 29.00 Cr..
• For Investments, as of Mar 2025, the value is 345.00 Cr.. The value appears to be declining and may need further review. It has decreased from 388.00 Cr. (Mar 2024) to 345.00 Cr., marking a decrease of 43.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,897.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,519.00 Cr. (Mar 2024) to 1,897.00 Cr., marking an increase of 378.00 Cr..
• For Total Assets, as of Mar 2025, the value is 4,274.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,988.00 Cr. (Mar 2024) to 4,274.00 Cr., marking an increase of 286.00 Cr..

Notably, the Reserves (3,418.00 Cr.) exceed the Borrowings (22.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for J B Chemicals & Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. It has decreased from 2.00 (Mar 23) to 1.00, marking a decrease of 1.00.
• For Basic EPS (Rs.), as of Mar 24, the value is 35.66. This value is within the healthy range. It has decreased from 53.00 (Mar 23) to 35.66, marking a decrease of 17.34.
• For Diluted EPS (Rs.), as of Mar 24, the value is 34.85. This value is within the healthy range. It has decreased from 52.34 (Mar 23) to 34.85, marking a decrease of 17.49.
• For Cash EPS (Rs.), as of Mar 24, the value is 44.52. This value is within the healthy range. It has decreased from 67.77 (Mar 23) to 44.52, marking a decrease of 23.25.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 188.36. It has decreased from 320.55 (Mar 23) to 188.36, marking a decrease of 132.19.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 188.36. It has decreased from 320.55 (Mar 23) to 188.36, marking a decrease of 132.19.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 224.50. It has decreased from 407.00 (Mar 23) to 224.50, marking a decrease of 182.50.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 60.19. This value is within the healthy range. It has decreased from 91.20 (Mar 23) to 60.19, marking a decrease of 31.01.
• For PBIT / Share (Rs.), as of Mar 24, the value is 51.28. This value is within the healthy range. It has decreased from 76.42 (Mar 23) to 51.28, marking a decrease of 25.14.
• For PBT / Share (Rs.), as of Mar 24, the value is 48.42. This value is within the healthy range. It has decreased from 71.76 (Mar 23) to 48.42, marking a decrease of 23.34.
• For Net Profit / Share (Rs.), as of Mar 24, the value is 35.61. This value is within the healthy range. It has decreased from 52.99 (Mar 23) to 35.61, marking a decrease of 17.38.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 35.61. This value is within the healthy range. It has decreased from 52.97 (Mar 23) to 35.61, marking a decrease of 17.36.
• For PBDIT Margin (%), as of Mar 24, the value is 26.81. This value is within the healthy range. It has increased from 22.40 (Mar 23) to 26.81, marking an increase of 4.41.
• For PBIT Margin (%), as of Mar 24, the value is 22.84. This value exceeds the healthy maximum of 20. It has increased from 18.77 (Mar 23) to 22.84, marking an increase of 4.07.
• For PBT Margin (%), as of Mar 24, the value is 21.56. This value is within the healthy range. It has increased from 17.63 (Mar 23) to 21.56, marking an increase of 3.93.
• For Net Profit Margin (%), as of Mar 24, the value is 15.86. This value exceeds the healthy maximum of 10. It has increased from 13.01 (Mar 23) to 15.86, marking an increase of 2.85.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is 15.86. This value is within the healthy range. It has increased from 13.01 (Mar 23) to 15.86, marking an increase of 2.85.
• For Return on Networth / Equity (%), as of Mar 24, the value is 18.90. This value is within the healthy range. It has increased from 16.52 (Mar 23) to 18.90, marking an increase of 2.38.
• For Return on Capital Employeed (%), as of Mar 24, the value is 25.45. This value is within the healthy range. It has increased from 19.71 (Mar 23) to 25.45, marking an increase of 5.74.
• For Return On Assets (%), as of Mar 24, the value is 13.83. This value is within the healthy range. It has increased from 11.53 (Mar 23) to 13.83, marking an increase of 2.30.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.01. This value is below the healthy minimum of 0.2. It has decreased from 0.15 (Mar 23) to 0.01, marking a decrease of 0.14.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.12. This value is within the healthy range. It has decreased from 0.22 (Mar 23) to 0.12, marking a decrease of 0.10.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.92. It has decreased from 1.02 (Mar 23) to 0.92, marking a decrease of 0.10.
• For Current Ratio (X), as of Mar 24, the value is 2.13. This value is within the healthy range. It has decreased from 2.76 (Mar 23) to 2.13, marking a decrease of 0.63.
• For Quick Ratio (X), as of Mar 24, the value is 1.56. This value is within the healthy range. It has decreased from 1.98 (Mar 23) to 1.56, marking a decrease of 0.42.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.75. This value is below the healthy minimum of 4. It has decreased from 1.87 (Mar 23) to 1.75, marking a decrease of 0.12.
• For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 28.40. This value is within the healthy range. It has decreased from 31.13 (Mar 23) to 28.40, marking a decrease of 2.73.
• For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 22.72. This value is within the healthy range. It has decreased from 24.33 (Mar 23) to 22.72, marking a decrease of 1.61.
• For Earning Retention Ratio (%), as of Mar 24, the value is 71.60. This value exceeds the healthy maximum of 70. It has increased from 68.87 (Mar 23) to 71.60, marking an increase of 2.73.
• For Cash Earning Retention Ratio (%), as of Mar 24, the value is 77.28. This value exceeds the healthy maximum of 70. It has increased from 75.67 (Mar 23) to 77.28, marking an increase of 1.61.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 21.07. This value is within the healthy range. It has increased from 19.57 (Mar 23) to 21.07, marking an increase of 1.50.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 13.47. This value is within the healthy range. It has increased from 12.37 (Mar 23) to 13.47, marking an increase of 1.10.
• For Enterprise Value (Cr.), as of Mar 24, the value is 25,860.24. It has increased from 15,719.76 (Mar 23) to 25,860.24, marking an increase of 10,140.48.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 7.42. This value exceeds the healthy maximum of 3. It has increased from 4.99 (Mar 23) to 7.42, marking an increase of 2.43.
• For EV / EBITDA (X), as of Mar 24, the value is 27.68. This value exceeds the healthy maximum of 15. It has increased from 22.28 (Mar 23) to 27.68, marking an increase of 5.40.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 7.35. This value exceeds the healthy maximum of 3. It has increased from 4.84 (Mar 23) to 7.35, marking an increase of 2.51.
• For Retention Ratios (%), as of Mar 24, the value is 71.59. This value exceeds the healthy maximum of 70. It has increased from 68.86 (Mar 23) to 71.59, marking an increase of 2.73.
• For Price / BV (X), as of Mar 24, the value is 8.76. This value exceeds the healthy maximum of 3. It has increased from 6.15 (Mar 23) to 8.76, marking an increase of 2.61.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 7.35. This value exceeds the healthy maximum of 3. It has increased from 4.84 (Mar 23) to 7.35, marking an increase of 2.51.
• For EarningsYield, as of Mar 24, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 23) which recorded 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness